NEW YORK – Beyond known factors like cancer stage and the presence of germline BRCA1 and BRCA2 mutations, methods for predicting outcomes for ovarian cancer patients are not well-established.
NEW YORK – Beyond known factors like cancer stage and the presence of germline BRCA1 and BRCA2 mutations, methods for predicting outcomes for ovarian cancer patients are not well-established.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.